Medivir's Annual Report for 2018 is Published
2018 was transformative year for Medivir. We managed to successfully move the projects in our clinical portfolio forward. We also decided on an increased focus on the further development of our clinical portfolio. This resulted in a reorganization where the company's administration and its activities in preclinical research were reduced and Medivir could enter 2019 with a slimmed organization that has a clear focus on the exciting clinical projects.
This and much more can be found in Medivir's Annual Report for 2018, published today at www.medivir.com.
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The company is investing in indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Collaborations and partnerships are important parts of Medivir's business model and the drug development as well as the commercialization is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.
For further information, please contact:
Interim CFO Medivir AB
Phone: +46 (0)73-125-1713
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Annual Report 2018 (PDF)
Press release (PDF)
Company Codes: Stockholm:MVIRB, Bloomberg:MVIRB@SS, ISIN:SE0000273294, RICS:MVIRB.ST